Veru, Inc. (VERU) Exploring Strategic Alternatives for its Legacy Female Health Business

Go back to Veru, Inc. (VERU) Exploring Strategic Alternatives for its Legacy Female Health Business

Veru Exploring Strategic Alternatives for its Legacy Female Health Business

March 8, 2021 8:30 AM EST

MIAMI, March 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer, today announced that it has engaged Morgan Stanley & Co. LLC as a financial advisor to assist the Company and its management in pursuing strategic alternatives regarding its legacy FC2 Female Condom® / FC2 Internal Condom business (FHC Business).

With the last two consecutive quarters for our FHC Business having set all-time historical records in terms of net revenues and gross profit, and with... More